当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Stability of liver fibrosis among HCV-infected injection drug users.

Stability of liver fibrosis among HCV-infected injection drug users.

Abstract：

BACKGROUND:There are few published data characterizing patterns of liver stiffness measurements (LSMs) among HCV-infected persons and their potential impact on clinical decisions (for example, deferring treatment and hepatocellular carcinoma surveillance). METHODS:A total of 591 HCV-infected injection drug users in a community-based cohort had four LSMs. We used semi-parametric latent class growth modelling to identify patterns, which then became a gold standard against which we characterized validity of information from the initial measurements. RESULTS:Median age was 49, 68% were male, 92% African-American and 33% HIV-coinfected. The median LSM at visit 1 was 6.7 kPa (IQR 5.3-8.8). Over a median 1.75 years, LSM measures were stable; median change between visits was 0 kPa (IQR -1.4-1.7). Only 3% had evidence of fibrosis progression. Other groups included stable patterns of no fibrosis (59%), moderate fibrosis (21%), severe fibrosis (7%) and cirrhosis (9%). Individuals with fibrosis progression were more likely to be HIV-infected than those with stable low fibrosis (P<0.001). The diagnostic accuracy of the first LSM for identification of need for cancer surveillance (cirrhosis ≥12.3 kPa) was high (positive predictive value =97%). Although no single low LSM had high negative predictive value for significant fibrosis (metavir <2), individuals with two or more low results rarely had progression. CONCLUSIONS:These data underscore the stability of liver fibrosis in a cohort of predominantly African-American HCV-infected persons over 1.75 years, support using LSMs to monitor untreated persons at risk for progression and assess need for hepatocellular carcinoma surveillance.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Mehta SH,Kirk GD,Astemborski J,Sulkowski MS,Afdhal NH,Thomas DL

doi

10.3851/IMP2085

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

813-21

issue

5

eissn

1359-6535

issn

2040-2058

journal_volume

17

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

    abstract：:The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Rusconi S,La Seta Catamancio S,Citterio P,Bulgheroni E,Kurtagic S,Galazzi M,Croce F,Moroni M,Galli M

    更新日期：2001-03-01 00:00:00

  • Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.

    abstract：BACKGROUND:Hepatitis delta virus (HDV) infection therapy is unclear. This systematic analysis aimed to clarify the evidence on the efficacy of interferon (IFN)-α-based therapy in HDV. METHODS:We performed a systematic search on electronic databases including MEDLINE (1970 to January 2011), Web of Science, The Cochrane...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2306

    authors： Lamers MH,Kirgiz ÖÖ,Heidrich B,Wedemeyer H,Drenth JP

    更新日期：2012-01-01 00:00:00

  • Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

    abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：10.3851/IMP1780

    authors： Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

    更新日期：2011-01-01 00:00:00

  • The host-pathogen interaction during HBV infection: immunological controversies.

    abstract：:HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1620

    authors： Bertoletti A,Maini MK,Ferrari C

    更新日期：2010-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期：2006-01-01 00:00:00

  • Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.

    abstract：BACKGROUND:Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy. Seven patients showed a delayed response to tenofovir. The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1940

    authors： Lada O,Gervais A,Branger M,Peytavin G,Roquebert B,Collin G,Fraqueiro G,Moucari R,Leclerc L,Martinot-Peignoux M,Matheron S,Marcellin P

    更新日期：2012-01-01 00:00:00

  • Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

    abstract：BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3851/IMP3205

    authors： Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

    更新日期：2018-01-01 00:00:00

  • Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.

    abstract：BACKGROUND:The multidrug resistance proteins (MRPs) form a subfamily within the ATP binding cassette transporters that confer resistance to a variety of structurally unrelated compounds. MRP4 has been reported to transport antiretroviral drugs out of cells in an active process. Although the main therapeutic effects of ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1468

    authors： Clemente MI,Alvarez S,Serramía MJ,Turriziani O,Genebat M,Leal M,Fresno M,Muñoz-Fernández MA

    更新日期：2009-01-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract：BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3197

    authors： Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期：2018-01-01 00:00:00

  • Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-

    abstract：BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3851/IMP1532

    authors： Paediatric European Network for Treatment of AIDS (PENTA).

    更新日期：2010-01-01 00:00:00

  • The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

    abstract：OBJECTIVES:Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We a...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Sternfeld T,Schmid M,Tischleder A,Mudra S,Schlamp A,Kost BP,Gruber R,Youle M,Bogner JR,Goebel FD

    更新日期：2007-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract：:Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Nolan D,John M,Mallal S

    更新日期：2001-09-01 00:00:00

  • A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS.

    abstract：BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,meta分析,评审

    doi：10.3851/IMP2726

    authors： Sprenger HG,Bierman WF,van der Werf TS,Gisolf EH,Richter C

    更新日期：2014-01-01 00:00:00

  • K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

    abstract：:Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe the surprising and consistent genotypic and phenotypic outcome in patients failing this combination. As part of a Da...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Røge BT,Katzenstein TL,Obel N,Nielsen H,Kirk O,Pedersen C,Mathiesen L,Lundgren J,Gerstoft J

    更新日期：2003-04-01 00:00:00

  • Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

    abstract：BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3372

    authors： Jia J,Shang J,Tang H,Jiang J,Ning Q,Dou X,Zhang S,Zhang M,Han T,Tan D,Zhou X,Chen G,Sheng J,Su Z,Chen H,Dai E,Ye Y,Guo Y,Shen Y,Yuan J,Wei Z,Zhu S,EVOLVE Study Group.

    更新日期：2020-10-22 00:00:00

  • A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings.

    abstract：:This article describes the development of a novel sequential sampling method for the surveillance of transmitted HIV drug resistance by cross-sectional survey. Two commonly used sequential sampling methods are described and their applicability to the problem of classifying the prevalence of transmitted HIV drug resist...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Myatt M,Bennett DE

    更新日期：2008-01-01 00:00:00

  • The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

    abstract：BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2015

    authors： Donegan KL,Walker AS,Dunn D,Judd A,Pillay D,Menson E,Lyall H,Tudor-Williams G,Gibb DM,Collaborative HIV Paediatric Study.,UK HIV Drug Resistance Database.

    更新日期：2012-01-01 00:00:00

  • Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.

    abstract：OBJECTIVE:To study decay rates of productively and latently infected cells in peripheral blood and lymph nodes during triple antiretroviral therapy and the possible impact of interleukin-2 (IL-2) on viral kinetics. METHODS:In this non-randomized study, nine antiretroviral-naive HIV-positive patients received either sa...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Stellbrink HJ,Hufert FT,Tenner-Racz K,Lauer J,Schneider C,Albrecht H,Racz P,van Lunzen J

    更新日期：1998-01-01 00:00:00

  • Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

    abstract：OBJECTIVE:To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART). DESIGN:We used a clinical database of HIV-infected patients to calculate the resource use and cost of care for different stages of HIV infection. Costs were incor...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yazdanpanah Y,Goldie SJ,Losina E,Weinstein MC,Lebrun T,Paltiel AD,Seage GR 3rd,Leblanc G,Ajana F,Kimmel AD,Zhang H,Salamon R,Mouton Y,Freedberg KA

    更新日期：2002-12-01 00:00:00

  • Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

    abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3036

    authors： Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

    更新日期：2016-01-01 00:00:00

  • Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

    abstract：BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP1931

    authors： Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

    更新日期：2011-01-01 00:00:00

  • Principles of HIV resistance testing and overview of assay performance characteristics.

    abstract：:HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several princi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Richman DD

    更新日期：2000-03-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract：BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP3202

    authors： Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期：2018-01-01 00:00:00

  • Management of hepatitis B patients with antiviral resistance.

    abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Fung SK,Lok AS

    更新日期：2004-12-01 00:00:00

  • Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.

    abstract：BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3377

    authors： Trunfio M,Salvador E,Gaviraghi A,Audagnotto S,Marinaro L,Motta I,Casciaro R,Ghisetti V,Fava C,Bonora S,Di Perri G,Calcagno A,e-COVID Study Group.

    更新日期：2021-01-18 00:00:00

  • Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

    abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Laufer N,Laguno M,Perez I,Cifuentes C,Murillas J,Vidal F,Bonet L,Veloso S,Gatell JM,Mallolas J

    更新日期：2008-01-01 00:00:00

  • Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

    abstract：BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3137

    authors： Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

    更新日期：2017-01-01 00:00:00

  • Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4

    abstract：OBJECTIVE:To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3. PATIENTS AND METHODS:Seventy patients with CD4<200 cells/mm3 and CV<1000 copies/ml were enrolled in a 6-month randomized con...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Delaugerre C,Gourlain K,Tubiana R,Carcelain G,Marcelin AG,Chouquet C,Mouroux M,Duvivier C,Autran B,Costagliola D,Katlama C,Calvez V

    更新日期：2003-06-01 00:00:00

  • Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.

    abstract：:The effectiveness of current antiretroviral therapies has led to more patients receiving long-term therapy, and increasing numbers of older patients. The complex interactions between HIV infection, ageing, comorbid conditions and drug-related toxicities, and their combined effects on patient health and quality of life...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1470

    authors： Boehme RE,Cameron S

    更新日期：2009-01-01 00:00:00

  • HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

    abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2425

    authors： Calle Serrano B,Manns MP

    更新日期：2012-01-01 00:00:00